Ultragenyx Pharmaceutical Inc. (RARE) financials

Ultragenyx Pharmaceutical Inc. (RARE) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Ultragenyx Pharmaceutical Inc. reported revenue of $673M, up 20.2% year over year, net income of -$575M, diluted EPS of -$5.83 and free cash flow of -$487M.

Revenue (fiscal 2025)

$673M

Revenue growth (fiscal 2025)

20.2%

Net income (fiscal 2025)

-$575M

Diluted EPS (fiscal 2025)

-$5.83

Free cash flow (fiscal 2025)

-$487M

Ultragenyx Pharmaceutical Inc. files with the U.S. Securities and Exchange Commission under CIK 0001515673, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.